While activation of the PI3K/AKT pathway is common in many cancers, and preclinical evidence for an oncogenic role for PIK3CA mutations is well accepted, mutations in PIK3CA have performed poorly as biomarkers for outcome in solid tumors [11]. This evidence concerns the gene PIK3CA and cancer.